Illumina, Inc. (VIE:ILMN)
Austria · Delayed Price · Currency is EUR | Market Cap | 39.68B +199.2% |
| Revenue (ttm) | 3.94B +4.9% |
| Net Income | 722.48M -34.4% |
| EPS | 4.81 -32.1% |
| Shares Out | n/a |
| PE Ratio | 54.45 |
| Forward PE | 50.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 259.65 |
| Previous Close | 258.30 |
| Day's Range | 259.65 - 261.95 |
| 52-Week Range | 81.72 - 269.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
Illumina Earnings Call Transcript: Q3 2026
Q3 revenue, margins and EPS beat guidance as clinical demand and NovaSeq X placements remained strong. FY26 revenue and EPS guidance rose; management sees high-single-digit consumables growth as the 2027 target and AI/data as longer-term opportunities.
Illumina Earnings release: Q3 2026
Illumina released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Illumina Slides: Q3 2026
Illumina has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Illumina Prepared remarks: Q3 2026
Illumina filed a regulatory document on October 29, 2026 disclosing important business information.
Illumina reports Q3 non-GAAP EPS $1.44, consensus $1.36
Reports Q3 revenue $1.13B, consensus $1.15B. “In Q3, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full…
Illumina raises FY26 EPS view to $5.40-$5.45 from $5.30-$5.40, consensus $5.36
Raises FY26 revenue view to $4.64B-$4.66B from $4.60B-$4.64B, consensus $4.62B.
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026...
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conf...
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Illumina downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213.
Stephens downgrades Illumina and 10x Genomics following outperformance
As previously reported, Stephens analyst Mason Carrico downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213, and 10x Genomics (TXG) to Equal…
Edwards Lifesciences added to ‘Core Ideas’ list at Evercore, Illumina removed
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $102 from $100 and keeps an Outperform rating on the shares, which were also added to the firm’s…
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and...
Illumina price target raised to $300 from $205 at Canaccord
Canaccord raised the firm’s price target on Illumina (ILMN) to $300 from $205 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results.
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Inc...
Illumina sets up commercial paper program for up to $1.0B
On October 8, Illumina (ILMN) “entered into definitive documentation to establish an unsecured commercial paper program pursuant to which the Company may issue short-term, unsecured commercial paper n...
Illumina price target raised to $270 from $210 at TD Cowen
TD Cowen raised the firm’s price target on Illumina (ILMN) to $270 from $210 and keeps a Hold rating on the shares. The firm adjusted targets in the life science…
Illumina price target raised to $168 from $140 at BofA
BofA raised the firm’s price target on Illumina (ILMN) to $168 from $140 and keeps an Underperform rating on the shares. The life science tools sector has further re-rated since…
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026....
Illumina releases SpliceAI2 to help advance rare disease research
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identi...
Illumina price target raised to $200 from $160 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $200 from $160 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
Illumina price target raised to $310 from $230 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Illumina (ILMN) to $310 from $230 and keeps an Outperform rating on the shares. The firm notes that its…
Illumina price target raised to $305 from $226 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Illumina (ILMN) to $305 from $226 and keeps a Buy rating on the shares. The firm adjusted its models and…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Illumina price target raised to $300 from $220 at Leerink
Leerink raised the firm’s price target on Illumina (ILMN) to $300 from $220 and keeps an Outperform rating on the shares. The firm cites comparable sales and incremental growth from…